Today, we’re excited to announce that Mighty Capital portfolio company, Mission Bio has raised a new $70 million Series C funding round, led by Novo Growth and including participation from Soleus Capital and existing investors Mayfield, Cota and Agilent. Mission Bio will use the funding to scale its Tapestri Platform, which uses the company’s work in single-cell multi-omics technology to help optimize clinical trials for targeted, precision cancer therapies.

Today, we’re excited to announce that Bluedot has raised a $9.1 million Series B funding led by Autotech Ventures, including participation by existing investor Transurban and new investors Forefront Ventures, IAG Firemark Ventures, and Mighty Capital. Alexei Andreev, from Autotech Ventures, has joined our board along with Jennifer Azapian, from Mighty Capital as a board observer.

Today, the six-year old startup announced that it has closed a $13 million Series A funding round led by Fusion Fund. Mighty Capital, Allianz Life Ventures, Vectr Fintech Partners and Viaduct Ventures also participated, along with two angel investors from a previous round.

Deal brings single-cell genomics to China and accelerates Mission Bio’s mission to predict and prevent cancer relapse on a global scale

Cancer is smart. Yes, you read that right.

The disease isn’t intelligent in the traditional sense — but cancer cells are adaptable, ‘learning’ from their environment and constantly evolving to improve survival. While targeted therapy can be effective at first, this evolution means that treatment resistance and disease progression remain a challenge.

To effectively combat cancer — to both detect it sooner and develop the most impactful, dynamic therapies — we need to be able to understand it. This means tracking the progression of each and every cancerous cell.

How top marketers are winning against digital-only disruptors by bringing location to the cloud.

Researchers at Rady Children’s Institute for Genomic Medicine (RCIGM) and its partners, including Fabric Genomics, have today published in Science Translational Medicine a new study documenting the process to diagnose rare genetic diseases in record time. This new method speeds answers to physicians and allows increased use of genome sequencing as a first-line diagnostic test for critically ill babies.

Mighty Capital, whose founder and managing partner is SC Moatti, has its first liquidity event. SC tells Women’s PE Briefs that the firm sold a small portion of its first investment, Amplitude.